Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

Study participants will undergo 3 study visits: baseline, day 7 (immediately post-therapy),
day 21 (2 weeks post-therapy). All participants will provide blood and stool samples at each
visit.

Inclusion Criteria:

- Diagnosis of end-stage renal disease

- Receiving chronic intermittent hemodialysis

Exclusion Criteria:

- Patients with less advanced kidney disease

- Inability or unwillingness to provide informed consent

- Patients who may be pregnant

- Hemodynamically unstable patients

- Patients with liver failure, pancreatic insufficiency, or inflammatory bowel disease

- Patients with ongoing or recent infection and those with history of C-diff infection

- Patients with abnormal bowel structure secondary to surgical or anatomic variations

- Patients on certain medications, including immunosuppressants, antidiarrheal agents,
or recent (within the last 2 months) use of antibiotics